Skip to main content

Table 4 Univariate and multivariate Cox models of DFS

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

  Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.034 0.998–1.070 0.061 1.036 0.850–2.637 0.043
BMI 0.989 0.930–1.053 0.739    
HR status 1.698 0.868–3.323 0.122 1.799 0.916–3.536 0.088
Menopausal status 1.393 0.795–2.442 0.247    
cN status 2.724 1.420–5.224 0.003 2.811 1.461–5.407 0.002
cT status 1.569 0.896–2.748 0.115 1.497 0.850–2.637 0.162
Zoledronic acid 0.656 0.371–1.160 0.147    
  1. Bold values indicate that P < 0.05
  2. DFS disease-free survival, HR hazard ratio, CI confidence interval, BMI body mass index
  3. the italicized data have a significance of > 0.05